356 related articles for article (PubMed ID: 17306521)
1. Regulatory T cells and cancer.
Wang HY; Wang RF
Curr Opin Immunol; 2007 Apr; 19(2):217-23. PubMed ID: 17306521
[TBL] [Abstract][Full Text] [Related]
2. Regulatory T cells and Toll-like receptors in tumor immunity.
Wang RF; Peng G; Wang HY
Semin Immunol; 2006 Apr; 18(2):136-42. PubMed ID: 16469504
[TBL] [Abstract][Full Text] [Related]
3. Regulatory T cells and toll-like receptors in cancer therapy.
Wang RF
Cancer Res; 2006 May; 66(10):4987-90. PubMed ID: 16707417
[TBL] [Abstract][Full Text] [Related]
4. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer.
Wang RF
Hum Immunol; 2008 Nov; 69(11):811-4. PubMed ID: 18817828
[TBL] [Abstract][Full Text] [Related]
5. Functional control of regulatory T cells and cancer immunotherapy.
Wang RF
Semin Cancer Biol; 2006 Apr; 16(2):106-14. PubMed ID: 16423537
[TBL] [Abstract][Full Text] [Related]
6. Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer.
Wang RF
Semin Cancer Biol; 2006 Feb; 16(1):73-9. PubMed ID: 16140545
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptors and immune regulation: their direct and indirect modulation on regulatory CD4+ CD25+ T cells.
Liu G; Zhao Y
Immunology; 2007 Oct; 122(2):149-56. PubMed ID: 17848162
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptors on regulatory T cells: expanding immune regulation.
Sutmuller RP; Morgan ME; Netea MG; Grauer O; Adema GJ
Trends Immunol; 2006 Aug; 27(8):387-93. PubMed ID: 16814607
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptors and immune regulation: implications for cancer therapy.
Wang RF; Miyahara Y; Wang HY
Oncogene; 2008 Jan; 27(2):181-9. PubMed ID: 18176599
[TBL] [Abstract][Full Text] [Related]
10. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
Conroy H; Marshall NA; Mills KH
Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
[TBL] [Abstract][Full Text] [Related]
11. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.
Degl'Innocenti E; Grioni M; Capuano G; Jachetti E; Freschi M; Bertilaccio MT; Hess-Michelini R; Doglioni C; Bellone M
Cancer Res; 2008 Jan; 68(1):292-300. PubMed ID: 18172322
[TBL] [Abstract][Full Text] [Related]
12. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
Kiniwa Y; Miyahara Y; Wang HY; Peng W; Peng G; Wheeler TM; Thompson TC; Old LJ; Wang RF
Clin Cancer Res; 2007 Dec; 13(23):6947-58. PubMed ID: 18056169
[TBL] [Abstract][Full Text] [Related]
13. The significance of Treg cells in defective tumor immunity.
Kosmaczewska A; Ciszak L; Potoczek S; Frydecka I
Arch Immunol Ther Exp (Warsz); 2008; 56(3):181-91. PubMed ID: 18512029
[TBL] [Abstract][Full Text] [Related]
14. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A
Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T cells and systemic lupus erythematosus.
Mudd PA; Teague BN; Farris AD
Scand J Immunol; 2006 Sep; 64(3):211-8. PubMed ID: 16918689
[TBL] [Abstract][Full Text] [Related]
16. Suppression of anti-cancer immunity by regulatory T cells: back to the future.
Orentas RJ; Kohler ME; Johnson BD
Semin Cancer Biol; 2006 Apr; 16(2):137-49. PubMed ID: 16376101
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.
Schabowsky RH; Madireddi S; Sharma R; Yolcu ES; Shirwan H
Curr Opin Investig Drugs; 2007 Dec; 8(12):1002-8. PubMed ID: 18058571
[TBL] [Abstract][Full Text] [Related]
18. Donor double-negative Treg promote allogeneic mixed chimerism and tolerance.
He KM; Ma Y; Wang S; Min WP; Zhong R; Jevnikar A; Zhang ZX
Eur J Immunol; 2007 Dec; 37(12):3455-66. PubMed ID: 18000953
[TBL] [Abstract][Full Text] [Related]
19. A CFSE based assay for measuring CD4+CD25+ regulatory T cell mediated suppression of auto-antigen specific and polyclonal T cell responses.
Venken K; Thewissen M; Hellings N; Somers V; Hensen K; Rummens JL; Stinissen P
J Immunol Methods; 2007 Apr; 322(1-2):1-11. PubMed ID: 17368474
[TBL] [Abstract][Full Text] [Related]
20. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
